Tilrdakizumab Almirall

University Hospital Schleswig-Holstein (UKSH)

Status: Active, not recruiting

Conditions: Psoriasis

Treatments: Biological: Tildrakizumab

Study type: Observational

Funder types: Other

Identifiers

NCT07244744

Tilrdakizumab Almirall

Details and patient eligibility

About

Define the mechanisms underlying the short- and the long-lasting effects of IL-23 targeting in plaque PsO, by characterizing the longitudinal effects of IL-23 inhibition on the ratio of Trm/Treg cells in the skin of moderate to severe plaque PsO patients. HDST (Visium HD) and HDSP (MICS) are used to characterize the early (2 weeks) and late (16 weeks) molecular effects of treatment with tildrakizumab on the skin of three patients with moderate to severe plaque psoriasis. Non-lesional and lesional skin samples taken at the start of treatment with tildrakizumab will be used, as well as healed skin adjacent to the original sampling sites at week 2 and week 16 after the start of treatment with tildrakizumab. The same samples will be examined using Visium HD and the MACSima imaging system.

Enrollment: 3 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients (18 years or older) with a diagnosis of moderate to severe chronic plaque psoriasis.
• Patients eligible for treatment with an IL-23 inhibitor, specifically Tildrakizumab.

Exclusion criteria

• Patients unable to comply with the study requirements.
• Known hypersensitivity to IL-23 inhibitors.

Trial design